Eastman Kodak Co said it hasacquired an 18.7 pct equity interest in Enzon Inc, apharmaceutical company specializing in protein therapy.    Kodak said it secured worldwide marketing rights for threeof Enzon's PEG enzymes used in the treatment of oxygen toxicitydisorders, hyperuricemia and gout.    The company said it acquired two mln Enzon shares for 15mln dlrs, with loans to Enzon of two mln dlrs and interest of30,000 dlrs credited against the purchase price.    Kodak said the drugs covered by the marketing rights are ininitial stages of the U.S. Food and Drug Administrationapproval process.  It said the investment should provide thenecessary capital to complete the FDA review process andprovide a marketing outlet for the drugs.    The drugs are PEG-superoxide disdmutase and PEG-catalase,for use against oxygen toxicity disorders that cause theoften-fatal tissue damage associated with severe burns, organtransplants, heart attacks and trauma, and PEG-uricase, fortreatment of gout and other conditions caused by the buildup ofhigh levels of uric acid in the body. Reuter&#3;